- Conditions
- Uveal Melanoma, Ocular Melanoma, Choroidal Melanoma
- Interventions
- Light-activated AU-011, Laser Activation
- Drug · Device
- Lead sponsor
- Aura Biosciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 13
- States / cities
- Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 7,359
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Rotator Cuff Tear
- Interventions
- Rotator Cuff Repair without Suprascapular Nerve decompression, Rotator Cuff Repair with Suprascapular Nerve decompression
- Procedure
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Evanston, Illinois
- Conditions
- Recurrent Glioblastoma
- Interventions
- CART-EGFR-IL13Ra2 T cells
- Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2042
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Brain Tumors
- Interventions
- 5-aminolevulinic acid
- Drug
- Lead sponsor
- David W. Roberts
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2013
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- carmustine, chemotherapy, cisplatin, etoposide, radiation therapy
- Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2008
- U.S. locations
- 19
- States / cities
- Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 16 more
- Conditions
- Headache
- Interventions
- Superficial Dry Needling, Non-thrust Mobilizations only
- Other
- Lead sponsor
- Youngstown State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 133 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Youngstown, Ohio
- Conditions
- Melanoma Metastatic
- Interventions
- Interleukin-2
- Drug
- Lead sponsor
- Western Regional Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Goodyear, Arizona
- Conditions
- Optic, Atrophy, Hereditary, Leber
- Interventions
- GS010, Sham Intravitreal Injection
- Biological · Device
- Lead sponsor
- GenSight Biologics
- Industry
- Eligibility
- 15 Years and older
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Atlanta, Georgia • Philadelphia, Pennsylvania
- Conditions
- Vestibular Schwannoma
- Interventions
- AAVAnc80-antiVEGF via Akouos Delivery Device
- Combination Product
- Lead sponsor
- Akouos, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Baltimore, Maryland • Rochester, Minnesota • Nashville, Tennessee + 1 more
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Interventions
- vorinostat, conventional surgery
- Drug · Procedure
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Melanoma
- Interventions
- Trametinib (GSK1120212), GSK2141795
- Drug
- Lead sponsor
- Adil Daud
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 2
- States / cities
- San Francisco, California • New York, New York
- Conditions
- Malignant Gliomas
- Interventions
- Gliolan®, Fluorescence-Guided Surgery
- Drug · Procedure
- Lead sponsor
- Constantinos Hadjipanayis
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 17
- States / cities
- Washington D.C., District of Columbia • Delray Beach, Florida • Atlanta, Georgia + 13 more
- Conditions
- Medulloblastoma
- Interventions
- Surgical resection, Ommaya/VPS, Methotrexate, Cisplatin, Vincristine, Cyclophosphamide, Carboplatin, Topotecan, Etoposide, Pegfilgrastim, Filgrastim, Irradiation, Educational and Media Intervention, SOC, Educational and Media Intervention
- Procedure · Drug · Radiation + 1 more
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 59 Months
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2035
- U.S. locations
- 10
- States / cities
- Palo Alto, California • Orlando, Florida • Tampa, Florida + 7 more
- Conditions
- Lymphoma, Prostate Cancer, Sarcoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- ganitumab, laboratory biomarker analysis, pharmacological study, biopsy
- Biological · Other · Procedure
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Orthodontic Appliance, Pain, Transcutaneous Electric Nerve Stimulation, Orthodontic Appliance Complication
- Interventions
- Active TENS Device, Intervention 2: Placebo/Sham Device
- Device
- Lead sponsor
- University of the Pacific
- Other
- Eligibility
- 12 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
- Interventions
- GR-MD-02, Placebo, Pembrolizumab
- Drug
- Lead sponsor
- Providence Health & Services
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Melanoma, Malignant Melanoma
- Interventions
- CT-011
- Drug
- Lead sponsor
- Medivation, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 16
- States / cities
- New Haven, Connecticut • Tampa, Florida • Chicago, Illinois + 9 more
- Conditions
- Metastatic Melanoma
- Interventions
- IN10018, Cobimetinib, Atezolizumab
- Drug · Biological
- Lead sponsor
- InxMed (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 5
- States / cities
- Miami, Florida • Boston, Massachusetts • New York, New York + 1 more
- Conditions
- Recurrent Astrocytoma, IDH-Mutant, Grade 3, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Recurrent Glioblastoma
- Interventions
- Biospecimen Collection, Chimeric Antigen Receptor T-Cell Therapy, Echocardiography, Fludeoxyglucose F-18, Intracranial Catheter Placement, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography, Resection
- Procedure · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Melanoma, Brain Metastases
- Interventions
- Craniotomy scheduled, Collection for non-craniotomy
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Neurofibromatosis Type 1 (NF1)
- Interventions
- Cholecalciferol
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 25 Years to 40 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio • Salt Lake City, Utah
- Conditions
- Melanoma
- Interventions
- Trametinib daily Until PD, CDX-3379 (ERBB3 antibody)
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC
- Interventions
- [212Pb]Pb-MP0712, [203Pb]Pb-MP0712
- Drug · Other
- Lead sponsor
- Molecular Partners AG
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 8
- States / cities
- Tampa, Florida • Atlanta, Georgia • Chicago, Illinois + 5 more
- Conditions
- Cancer, Melanoma, Ovary Cancer, Pancreatic Cancer, Solid Tumor
- Interventions
- ENB003, Pembrolizumab
- Drug
- Lead sponsor
- ENB Therapeutics, Inc
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Houston, Texas